Filing Details
- Accession Number:
- 0000899243-19-019317
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-07-08 17:35:08
- Reporting Period:
- 2019-07-05
- Accepted Time:
- 2019-07-08 17:35:08
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1552451 | Myokardia Inc | MYOK | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1413822 | Anastasios Gianakakos | C/O Myokardia, Inc. 333 Allerton Avenue South San Francisco CA 94080 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-06-18 | 39,000 | $0.00 | 116,470 | No | 5 | G | Direct | |
| Common Stock | Disposition | 2019-06-18 | 39,000 | $0.00 | 49,473 | No | 5 | G | Indirect | By Reporting Person's Trust 2 |
| Common Stock | Disposition | 2019-07-05 | 1,550 | $49.13 | 114,920 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-07-05 | 2,450 | $50.10 | 112,470 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 5 | G | Direct | |
| No | 5 | G | Indirect | By Reporting Person's Trust 2 |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 49,473 | Indirect | By Reporting Person's Trust 2 |
| Common Stock | 500,000 | Indirect | By Reporting Person's Trust 3 |
| Common Stock | 12,200 | Indirect | By Trust 1 |
| Common Stock | 12,200 | Indirect | By Trust 2 |
| Common Stock | 12,200 | Indirect | By Trust 3 |
Footnotes
- Transfer of shares to Reporting Person from Reporting Person's Trust 2.
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- Represents the weighted average sale price of the shares sold ranging from $48.68 to $49.59 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- Represents the weighted average sale price of the shares sold ranging from $49.82 to $50.49 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Billionaire Hedge Funds
